HIV Research Today is a free monthly online journal that collates and summarizes the latest research about HIV, including details on human immunodeficiency virus, testing, treatment, prevention, vaccines, aids.

Volume 2 (2005), Issue 9 (September)

1. p73 Interacts with human immunodeficiency virus type 1 Tat in astrocytic cells and prevents its acetylation on lysine 28.
   Mol Cell Biol, 25(18): 8126-38. [Abstract] [Full-text]
2. The effect of malaria on mortality in a cohort of HIV-infected Ugandan adults.
   Trop Med Int Health, 10(9): 894-900. [Abstract] [Full-text]
3. Unique acquisition of cytotoxic T-lymphocyte escape mutants in infant human immunodeficiency virus type 1 infection.
   J Virol, 79(18): 12100-5. [Abstract] [Full-text]
4. Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity.
   J Virol, 79(18): 12088-94. [Abstract] [Full-text]
5. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
   J Virol, 79(18): 12045-57. [Abstract] [Full-text]
6. Integration targeting by avian sarcoma-leukosis virus and human immunodeficiency virus in the chicken genome.
   J Virol, 79(18): 12035-44. [Abstract] [Full-text]
7. Molecular footprint of drug-selective pressure in a human immunodeficiency virus transmission chain.
   J Virol, 79(18): 11981-9. [Abstract] [Full-text]
8. Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain.
   J Virol, 79(18): 11952-61. [Abstract] [Full-text]
9. Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity.
   J Virol, 79(18): 11848-57. [Abstract] [Full-text]
10. Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus.
    J Virol, 79(18): 11742-51. [Abstract] [Full-text]
11. In-depth analysis of a heterosexually acquired human immunodeficiency virus type 1 superinfection: evolution, temporal fluctuation, and intercompartment dynamics from the seronegative window period through 30 months postinfection.
    J Virol, 79(18): 11693-704. [Abstract] [Full-text]
12. Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells.
    J Virol, 79(18): 11598-606. [Abstract] [Full-text]
13. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles.
    J Virol, 79(18): 11580-7. [Abstract] [Full-text]
14. The functionally exchangeable L domains in RSV and HIV-1 Gag direct particle release through pathways linked by Tsg101.
    Traffic, 6(10): 880-94. [Abstract] [Full-text]
15. HIV-1 Nef-induced FasL induction and bystander killing requires p38 MAPK activation.
    Blood, 106(6): 2059-68. [Abstract] [Full-text]
16. Discordance between viral loads determined by Roche COBAS AMPLICOR human immunodeficiency virus type 1 monitor (version 1.5) Standard and ultrasensitive assays caused by freezing patient plasma in centrifuged becton-dickinson vacutainer brand plasma preparation tubes.
    J Clin Microbiol, 43(9): 4635-9. [Abstract] [Full-text]
17. Genotyping of B and non-B subtypes of human immunodeficiency virus type 1.
    J Clin Microbiol, 43(9): 4623-7. [Abstract] [Full-text]
18. Major histocompatibility complex class II (HLA-DRB and -DQB) allele frequencies in Botswana: association with human immunodeficiency virus type 1 infection.
    Clin Diagn Lab Immunol, 12(9): 1020-8. [Abstract] [Full-text]
19. Characteristics associated with suboptimal viral suppression at delivery in human immunodeficiency virus-1-infected pregnant women.
    Am J Obstet Gynecol, 193(3): 1266-9. [Abstract] [Full-text]
20. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.
    Vaccine, 23(42): 5009-21. [Abstract] [Full-text]
21. Human immunodeficiency virus type 1 gp120 and other activation stimuli are highly effective in triggering alpha interferon and CC chemokine production in circulating plasmacytoid but not myeloid dendritic cells.
    J Virol, 79(19): 12597-601. [Abstract] [Full-text]
22. Lys-34, dispensable for integrase catalysis, is required for preintegration complex function and human immunodeficiency virus type 1 replication.
    J Virol, 79(19): 12584-91. [Abstract] [Full-text]
23. Patterns of cytokine production in human immunodeficiency virus type 1 (HIV-1)-specific human CD8+ T cells after stimulation with HIV-1-infected CD4+ T cells.
    J Virol, 79(19): 12536-43. [Abstract] [Full-text]
24. Simian immunodeficiency virus infection in free-ranging sooty mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d'Ivoire: implications for the origin of epidemic human immunodeficiency virus type 2.
    J Virol, 79(19): 12515-27. [Abstract] [Full-text]
25. Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease.
    J Virol, 79(19): 12477-86. [Abstract] [Full-text]
26. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    J Virol, 79(19): 12447-54. [Abstract] [Full-text]
27. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
    J Virol, 79(19): 12321-31. [Abstract] [Full-text]
28. Impact of the placental cytokine-chemokine balance on regulation of cell-cell contact-induced human immunodeficiency virus type 1 translocation across a trophoblastic barrier in vitro.
    J Virol, 79(19): 12304-10. [Abstract] [Full-text]
29. V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.
    J Virol, 79(19): 12296-303. [Abstract] [Full-text]
30. Regulation of human immunodeficiency virus type 1 envelope glycoprotein fusion by a membrane-interactive domain in the gp41 cytoplasmic tail.
    J Virol, 79(19): 12231-41. [Abstract] [Full-text]
31. Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1.
    J Virol, 79(19): 12199-204. [Abstract] [Full-text]
32. Comparing antigenicity and immunogenicity of engineered gp120.
    J Virol, 79(19): 12148-63. [Abstract] [Full-text]
33. Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1.
    J Virol, 79(19): 12132-47. [Abstract] [Full-text]
34. Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection.
    J Neurovirol, 11(4): 319-28. [Abstract] [Full-text]
35. AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS.
    Am J Physiol Heart Circ Physiol, 289(4): H1373-80. [Abstract] [Full-text]
36. MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.
    Int J Immunogenet, 32(5): 269-71. [Abstract] [Full-text]
37. Adaptation, co-evolution, and human susceptibility to HIV-1 infection.
    Infect Genet Evol, 5(4): 327-34. [Abstract] [Full-text]
38. Interleukin-10 induces inhibitory C/EBPbeta through STAT-3 and represses HIV-1 transcription in macrophages.
    Am J Respir Cell Mol Biol, 33(4): 406-11. [Abstract] [Full-text]
39. Opportunistic infection as a cause of transient viremia in chronically infected HIV patients under treatment with HAART.
    Bull Math Biol, 67(6): 1227-51. [Abstract] [Full-text]
40. Dynamic treatment model to examine the association between phenotypic drug resistance and duration of HIV viral suppression.
    Bull Math Biol, 67(6): 1315-32. [Abstract] [Full-text]
41. Progress in targeting HIV-1 entry.
    Drug Discov Today, 10(16): 1085-94. [Abstract] [Full-text]
42. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
    J Med Virol, 77(3): 337-44. [Abstract] [Full-text]
43. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097).
    J Med Virol, 77(3): 345-50. [Abstract] [Full-text]
44. Vertical transmission of HIV in Ghanaian women diagnosed in cord blood and post-natal samples.
    J Med Virol, 77(3): 351-9. [Abstract] [Full-text]
45. Changing association between schooling levels and HIV-1 infection over 11 years in a rural population cohort in south-west Uganda.
    Trop Med Int Health, 10(10): 993-1001. [Abstract] [Full-text]
46. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.
    J Virol, 79(20): 13060-9. [Abstract] [Full-text]
47. Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein.
    J Virol, 79(20): 13028-36. [Abstract] [Full-text]
48. De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection.
    J Virol, 79(20): 12952-60. [Abstract] [Full-text]
49. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.
    J Virol, 79(20): 12773-82. [Abstract] [Full-text]
50. Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response.
    J Virol, 79(20): 12763-72. [Abstract] [Full-text]
51. Reconstitution and molecular analysis of an active human immunodeficiency virus type 1 Nef/p21-activated kinase 2 complex.
    J Virol, 79(20): 12732-41. [Abstract] [Full-text]
52. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression.
    J Virol, 79(20): 12674-80. [Abstract] [Full-text]
53. Distinct functional sites for human immunodeficiency virus type 1 and stromal cell-derived factor 1alpha on CXCR4 transmembrane helical domains.
    J Virol, 79(20): 12667-73. [Abstract] [Full-text]

© 2004-2008 HIV Research Today. All Rights Reserved.